COMP <GO>
SNY vs REGN // ALTMAN Z-SCORE & DEBT/EQUITY
Sanofi ADS (NASDAQ) VS. Regeneron Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: SNY 3
— REGN 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: REGN
LAST: $44.34 (+2.81%) • MKT CAP: $105.19B
balance-sheet
3.74
LAST: $927.89 (+13.33%) • MKT CAP: $84.30B
balance-sheet
7.72
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SNY VS. REGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SNY | REGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 9.40% | +0.50 | SNY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 20.2x | +0.80 | REGN | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 5.14% | -2.93 | REGN | /fcf-yield <GO> |
| Operating Margin | 13.90% | 24.90% | -11.00 | REGN | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 31.40% | -20.50 | REGN | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 1.00% | -2.10 | REGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.44% | -0.44 | REGN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.74 | 7.72 | -3.98 | REGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | REGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.8 | 53.0 | +5.80 | SNY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.14 | 1.16 | -0.02 | REGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.5x | 17.4x | +13.10 | REGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $105.19B | $84.30B | $20.89B | SNY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SNY REV | REGN REV | SNY GROSS % | REGN GROSS % | SNY FCF | REGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $14.34B | — | — | — | $4.33B |
| FY 2024 | — | $14.20B | — | — | — | $3.78B |
| FY 2023 | — | $13.12B | — | — | — | $4.00B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SNY // BETA 1.14
REGN // BETA 1.16